Checkpoint inhibitors and the changing face of the relapsed/refractory classical hodgkin lymphoma pathway

HIGHLIGHTS

• who: Xiao-Yin Zhang from the Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK have published the research: Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway, in the Journal: (JOURNAL)
• what: The authors aim to discuss the use of CPIs in different relapsed/refractory settings in an effort to better define their role and highlight areas of research. Following on the success Current Oncology Reports 24:1477-1488 of this approach, the safety and efficacy of post-ASCT consolidation with CPI alone or in combination . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.